Plain-English translation of NCT07177352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a screening study designed to help identify whether you might be a good fit for future Alzheimer's disease research trials. Researchers will assess your memory and thinking abilities using a simple test, and take a blood sample to measure a specific protein (pTau217) that may be related to Alzheimer's disease. The goal is to determine who would be eligible for the next phase of testing or treatment studies.
Alzheimer's disease affects millions of people, and researchers need to find participants who are in the early stages of the disease to test new approaches. This screening study makes it easier to identify the right people quickly and fairly, so more people can potentially benefit from new research opportunities.
You likely qualify if…
You likely don't qualify if…
As a participant, you would complete a memory test called the International Shopping List Test, which assesses how well you can remember information. You would also have a blood draw so researchers can measure the protein pTau217. This screening visit is designed to be relatively straightforward, and the results will help determine whether you might be eligible for future Alzheimer's research studies.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States